ResearchIn-Press PreviewCOVID-19
Open Access | 10.1172/jci.insight.145785
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Chouchane, L. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Grivel, J. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Farag, E. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by
Pavlovski, I.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Maacha, S. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Sathappan, A. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Al-Romaihi, H. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Abuaqel, S. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Ata, M. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Ismail Chouchane, A. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Remadi, S. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Halabi, N. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Rafii, A. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by Al-Thani, M. in: JCI | PubMed | Google Scholar
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by
Marr, N.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by
Subramanian, M.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, United States of America
2Deep Phenotyping Core, Sidra Medicine, Doha, Qatar
3Department of Communicable Diseases Control, Ministry of Public Health, Doha, Qatar
4Department of Immunology, Sidra Medicine, Doha, Qatar
5Laboratoire CYTOPATH, Cytopath, Sousse, Tunisia
6Department of Genetic Medicine, Weill Cornell Medicine, New York City, United States of America
7Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Doha, Qatar
8Ministry of Public Health, Ministry of Public Health, Doha, Qatar
Find articles by
Shan, J.
in:
JCI
|
PubMed
|
Google Scholar
|
Published February 2, 2021 - More info
The development of prophylactic and therapeutic agents for coronavirus disease 2019 (COVID-19) is a current global health priority. Here, we investigated the presence of cross-neutralizing antibodies against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) in dromedary camels that were Middle East respiratory syndrome (MERS)-CoV-seropositive but MERS-CoV-free. The tested 229 dromedaries had anti-MERS-CoV camel antibodies with variable cross-reactivity patterns against SARS-CoV-2 proteins, including the S trimer, M, N, and E proteins. Using SARS-CoV-2 competitive immunofluorescence immunoassays and pseudovirus neutralization assays, we found medium-to-high titers of cross-neutralizing antibodies against SARS-CoV-2 in these animals. Through linear B cell epitope mapping using phage immunoprecipitation sequencing and a SARS-CoV-2 peptide/proteome microarray, we identified a large repertoire of betacoronavirus cross-reactive antibody specificities in these dromedaries and demonstrated that the SARS-CoV-2-specific VHH antibody repertoire is qualitatively diverse. This analysis revealed not only several SARS-CoV-2 epitopes that are highly immunogenic in humans, including a neutralizing epitope, but also epitopes exclusively targeted by camel antibodies. The identified SARS-CoV-2 cross-neutralizing camel antibodies are not proposed as a potential treatment for COVID-19. Rather, their presence in non-immunized camels supports the development of SARS-CoV-2 hyperimmune camels, which could be a prominent source of therapeutic agents for the prevention and treatment of COVID-19.